Sona Deshmukh, MBBS, MPH

CRS:

BJMC

Role:

Research Staff

Position:

Study Coordinator

Dr. Deshmukh is Study Coordinator for the Tuberculosis-Diabetes study at the Byramjee Jeejeebhoy Government Medical College-JHU Clinical Research Site, funded by the NIH/National Institute of Allergy and Infectious Diseases (NIAID). Her research interests include the epidemiology of noncommunicable diseases and policy reforms for the same.

The BJGMC Clinical Research Site is a member of a the Baltimore-Washington-India Clinical Trials Unit, a collaborative research partnership among BJGMC, Johns Hopkins School of Medicine, and Whitman Walker Health in Washington, DC, to conduct clinical research for the world’s largest HIV therapeutic trial networks: the AIDS Clinical Trials Group (ACTG) and the International Maternal Pediatric and Adolescent AIDS Clinical Trial Network (IMPAACT).

Dr. Deshmukh has more than five years of experience in public health, programme management, policy design, and community-based research studies for noncommunicable diseases. She has published two research publications. Following a short tenure as Medical Officer in a government hospital, she worked under the dynamic leadership of Dr. Abhay Bang for two years in their esteemed research organization SEARCH, in Gadchiroli, India. Here she designed, implemented, and managed various community-based research projects conducted in 86 villages in Gadchiroli.

Further she took the opportunity to work in the state health department for three years as District Programme Officer to implement and monitor the National Programme for Prevention and Control of Non Communicable Diseases in Chandrapur, Maharashtra. Following her field experience, she briefly served for six months as a senior consultant for public health to government of Maharashtra.

Dr. Deshmukh received a MBBS in medicine from Maharashtra University of Health Sciences in Nashik, India, and a Master of Public Health degree from Tata Institute of Social Sciences (TISS) in Mumbai, India.

Categories

Leadership Committees
CRS
Roles

Clinical Trials

A5332: Randomized Trial to Prevent Vascular Events in HIV...

REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....

Read More

A5346: Sitagliptin for Reducing Inflammation and Immune...

The purpose of the study is to evaluate whether sitagliptin (Januvia is the brand name for sitagliptin)...

Read More

A5327: Sofosbuvir + Ribavirin w/o Interferon for Treatment...

A5327 SWIFT-C is a Phase I, open-label, two-cohort clinical trial, in which between 44 and 50 acutely HCV-infected HIV-1...

Read More

A5314: Effect of LDMTX on Inflammation in HIV-infected...

A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...

Read More

A5207, Maintaining Options for Mothers Study (MOMS): A Phase...

A major disadvantage of giving SD NVP is the potential for maternal development of NVP resistance and additional resistance to...

Read More